Neil Liebowitz
Psychiatry · Southington, CTNPI 1609835362
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 414 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 47.4% of the total. Reporting peaked in 2021 at $2,141 and has fallen 98.6% since, to $31 in 2025. Among psychiatry clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 414 payments — averaging $14.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$3K
- AbbVie$510
- Lundbeck LLC$509
- Johnson & Johnson$482
- Takeda Pharmaceuticals U.S.A., Inc.$331
- Neurocrine Biosciences, Inc.$222
- plus $1K from 15 others
What the payments were for
- Food & beverage$5,97599%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 223 | $2,849 |
| AbbVie(2 entities) | 52 | $510 |
| Lundbeck LLC | 25 | $509 |
| Johnson & Johnson | 28 | $482 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $331 |
| Neurocrine Biosciences, Inc. | 9 | $222 |
| Jazz Pharmaceuticals Inc. | 9 | $193 |
| Eisai Inc. | 9 | $188 |
| Otsuka America Pharmaceutical, Inc. | 8 | $133 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $132 |
| Teva Pharmaceuticals USA, Inc. | 5 | $98 |
| Avanir Pharmaceuticals, Inc. | 4 | $90 |
| Adlon Therapeutics L.p. | 4 | $84 |
| Ironshore Pharmaceuticals Inc. | 3 | $47 |
| Almatica Pharma LLC | 2 | $36 |
| Merck | 2 | $35 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,015 in reported general payments places this provider in the 90th percentile of 644 psychiatry providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clonazepam | 11 | $230 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Southington
- Vladimir CoricNew Haven$133.7M
- Donald AmmermanDanbury$1.5M
- Joseph GoldbergNew Canaan$914K
- Lisa HardingMilford$608K
- Tarique PereraDanbury$383K
- John GelinasDanbury$364K
- Irene AbramovichWest Hartford$352K
- Robert BermanNew Haven$126K
- John KrystalWest Haven$122K
- David MatuskeyFarmington$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.